Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SQUIBB's CAPOTEN COULD GET ONCE-DAILY ANTIHYPERTENSIVE CLAIM; ADVISORY COMMITTEE SUGGESTS INCLUDING ONCE-DAILY INFORMATION IN CLINICAL PHARMACOLOGY SECTION

Executive Summary

Squibb's Capoten labeling should be able to mention in the Clinical Pharmacology section once-a-day efficacy for hypertension when used with a diuretic, FDA's Cardio-Renal Drugs Advisory Committee unanimously agreed (with one abstention) at its May 5 meeting. The recommendation also presumably applies to Capozide (captopril/hydrochlorothiazide). Both Capoten and Capozide labeling currently recommend b.i.d. or t.i.d. administration for hypertension. A labeling change in the Clinical Pharmacology section noting 24-hour duration could be followed later by a change in the Dosage and Administration section. FDA noted at the meeting that Squibb had requested that the once-daily information be added to the Clinical Pharmacology section pending the submission of more complete data to support a full-fledged; once-daily antihypertensive claim. The study that was identified by the committee as most persuasive found that the change from baseline (minus placebo) in seated diastolic blood pressure at the end of the 24-hour dosing interval and after eight weeks of therapy was 6.22 mm Hg for patients receiving captopril 50 mg and hydrochlorothiazide 25 mg; 4.22 mm Hg for patients receiving captropril 25 mg and hydrochlorothiazide 12.5 mg; 1.72 mm Hg for patients receiving hydrochlorothiazide 12.5 mg; and 1.27 mm Hg for patients receiving captopril 25 mg. The committee also considered changing the recommended t.i.d. Capoten dosage regimen for congestive heart failure to a b.i.d. schedule, but voted four to two that a submitted studies did not sufficiently support such a change. Several committee members, however, commented that they "intuitively" believe a b.i.d. regimen is effective and pointed out that a b.i.d. v. t.i.d. study found essentially similar effects of the two regimens on exercise endurance and other efficacy parameters. The committee additionally evaluated two studies on the effect of captopril on ventricular function in post-myocardial infarction patients. One of the studies found an improvement in hemodynamic function compared to placebo, while the other showed no statistical difference compared to placebo, but did find a benefit over the baseline period. The committee agreed that the studies did not provide any conclusive information about captopril's effect in the post-MI population, but said the data looked promising. The committee noted that more conclusive results should be obtained from the ongoing SAVE study, which is evaluating survival effects of Capoten in roughly 2,000 post-MI patients. Results from that study are not expected before 1991.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel